Skip to main content
. Author manuscript; available in PMC: 2024 Jun 1.
Published in final edited form as: Gastroenterology. 2023 Mar 7;164(7):1279–1292. doi: 10.1053/j.gastro.2023.02.043

Figure 2. The mevalonate-squalene-cholesterol biosynthesis pathway regulates TAZ expression in HCC.

Figure 2.

A. Following cholesterol depletion, Huh7 and PLC/PRF/5 cells were incubated with cholesterol-enriched liposomes, and TAZ expression was assessed by WB. B. Schematic of the mevalonate pathway and pharmacologic inhibitors. TAZ and YAP expression assessed by WB in Huh7 treated with inhibitors of the mevalonate pathway. C. Effect of HMGCR, FDFT1 and SREBP2 silencing on TAZ expression in Huh7 cells. D,E. SREBP2 deletion in the MET+CTNNB1S45Y model. TAZ expression assessed by WB and immunofluorescent staining (n=7 Srebp2fl/fl and n=7 Srebp2ΔHep mice) (D). HCC development was assessed by LW/BW ratio, tumor number and tumor size (E, n=10 Srebp2fl/fl and n=11 Srebp2ΔHep mice). Scale bar (D): 100 μm, (E): 1 cm.